Document Detail


Clopidogrel: a case for indication-specific pharmacogenetics.
MedLine Citation:
PMID:  22513313     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.
Authors:
J A Johnson; D M Roden; L J Lesko; E Ashley; T E Klein; A R Shuldiner
Related Documents :
11323203 - Genetic parameter estimates for pre-weaning weight traits in dorper sheep.
9267523 - Quick method for confirmation of quantitative trait loci.
23000143 - A noncoding, regulatory mutation implicates hcfc1 in nonsyndromic intellectual disability.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  91     ISSN:  1532-6535     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-19     Completed Date:  2012-06-07     Revised Date:  2014-05-08    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  774-6     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Balloon, Coronary*
Aryl Hydrocarbon Hydroxylases / genetics*
Genotype
Humans
Pharmacogenetics
Platelet Aggregation Inhibitors / adverse effects*
Ticlopidine / adverse effects,  analogs & derivatives*
Grant Support
ID/Acronym/Agency:
R01 HL105993/HL/NHLBI NIH HHS; R01 NS073346/NS/NINDS NIH HHS; R01 NS073346/NS/NINDS NIH HHS; R24 GM61374/GM/NIGMS NIH HHS; U01 GM061374/GM/NIGMS NIH HHS; U01 GM074492/GM/NIGMS NIH HHS; U01 GM074492/GM/NIGMS NIH HHS; U01HL105198/HL/NHLBI NIH HHS; U19 HL065962/HL/NHLBI NIH HHS; U19 HL065962/HL/NHLBI NIH HHS; UL1 TR000064/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; A74586SNO7/clopidogrel; EC 1.14.14.1/Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1/CYP2C19 protein, human; OM90ZUW7M1/Ticlopidine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The need for translational research on drug-drug interactions.
Next Document:  Right Ventricular Longitudinal Peak Systolic Strain Measurements from the Subcostal View in Patients...